Der Onkologe

, Volume 18, Issue 8, pp 699–704


Therapieoptionen beim lokalisierten und disseminierten Rezidiv


Metastasierte bzw. lokal rezidivierte und nicht mehr R0-resektable Analkarzinome stellen eine therapeutische Herausforderung dar, weil infolge der geringen Inzidenz des Tumors und der Seltenheit von Metastasen nach adäquater Radiochemotherapie nach wie vor nur sehr wenige Daten zur medikamentösen Therapie vorliegen. Aus der älteren Literatur lässt sich ableiten, dass Cisplatin/5-Fluorouracil-haltige Protokolle eine sinnvolle Primärtherapie bei eingetretener Metastasierung darstellen und daher empfohlen werden können. Das mediane Überleben liegt mit diesen Therapien in etwa bei 12–15 Monaten. Mehrere Fallberichte zeigen darüber hinaus, dass aus der Gruppe der molekulargezielten Therapien insbesondere der EGFR-Antikörper Cetuximab vielversprechende Ergebnisse gezeigt hat. Vor einer Therapieeinleitung sollte jedoch nach Ansicht der Autoren eine KRAS-Analyse erwogen werden. Der Versuch einer primären oder sekundären Metastasenresektion erscheint bei möglicher R0-Resektion gerechtfertigt.


Analkarzinom Cetuximab Palliativtherapie Rezidiv KRAS 

Anal cancer

Therapy options for localized and disseminated recurrence


Metastasized, local recurrent and non-resectable R0 anal carcinomas represent a therapeutic challenge because due to the low incidence of the tumor and the rarity of metastases following adequate radiochemotherapy, only very little data on medication therapy is available. From the older literature it can be derived that protocols with cisplatin/5-fluorourcil represent a reasonable primary therapy when metastases are present and can therefore be recommended. Using this therapy the mean survival is approximately 12-15 months. Furthermore, several case reports have documented that the group of molecular targeted therapies, especially with the epidermal growth factor receptor (EGFR) antibody cetuximab, has shown promising results. However, in the opinion of the authors a KRAS analysis should be initiated before induction of therapy. Attempts at primary or secondary resection of metastases by a possible R0 resection seem to be justified.


Anal cancer Cetuximab Palliative treatment Recurrence KRAS 


  1. 1.
    Ajani J, Carrasco CH, Jackson DE, Wallace S (1989) Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 87:221–224PubMedCrossRefGoogle Scholar
  2. 2.
    Alcindor T (2008) Activity of paclitaxel in metastatic squamous anal carcinoma. Int J Colorectal Dis 23:171CrossRefGoogle Scholar
  3. 3.
    Alvarez G, Perry A, Tan BR, Wang HL (2006) Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 19(7):942–949PubMedCrossRefGoogle Scholar
  4. 4.
    Daling JR, Madeleine MM, Johnson LG et al (2004) Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101(2):270–280PubMedCrossRefGoogle Scholar
  5. 5.
    Damascelli B, Cantù G, Mattavelli F et al (2001) Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92:2592–2602PubMedCrossRefGoogle Scholar
  6. 6.
    De Dosso S, Martin V, Zanellato E et al (2010) Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori 96(4):627–628Google Scholar
  7. 7.
    Eng C et al (2012) Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. Abstract Nummer 4116 bei Gastrointestinal Cancers Symposium of American Society of Clinical Oncology (ASCO)Google Scholar
  8. 8.
    Evesque L, Etienne-Grimaldi M, Peyrottes I et al (2010) KRAS and BRAF mutation status in squamous cell carcinoma (SCC) of the anal canal. Poster Presentation at Gastrointestinal Cancers Symposium of American Society of Clinical Oncology (ASCO)Google Scholar
  9. 9.
    Faivre C, Rougier P, Ducreux M et al (1999) 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 86:861–865PubMedGoogle Scholar
  10. 10.
    Golub DV, Civelek AC, Sharma VR (2011) A regimen of taxol, ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract:163736 [Epub 2011 Jun 15]Google Scholar
  11. 11.
    Grabenbauer GG, Kessler H, Matzel KE et al (2005) Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum 48:1742–1751PubMedCrossRefGoogle Scholar
  12. 12.
    Grifaichi F, Padobani A, Romeo F et al (2001) Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. Tumori 87:58–59PubMedGoogle Scholar
  13. 13.
    Hofheinz R-D (2007) Analkarzinom: Therapieoptionen beim lokalisierten und disseminierten Rezidiv. Onkologe. DOI 10.1007/s00761-007-1268-yGoogle Scholar
  14. 14.
    Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRefGoogle Scholar
  15. 15.
    Jhawer M, Mani S, Lefkopoulou M (2006) Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Invest New Drugs 24:447–454PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson LG, Madeleine MM, Newcomer LM et al (2004) Anal cancer incidence and survival: the surveilance, epidemiology, and end results experience, 1973–2000. Cancer 101(2):281–288PubMedCrossRefGoogle Scholar
  17. 17.
    Le LH, Chetty R, Moore MJ (2005) Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol 124:20–23PubMedCrossRefGoogle Scholar
  18. 18.
    Lukan N, Ströbel P, Willer A et al (2009) Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 77(5):293–299PubMedCrossRefGoogle Scholar
  19. 19.
    Magill GB, Quan SHQ (1989) Salvage chemotherapy of anal epidermoid carcinoma with cisplatin based protocols. Proc Am Soc Clin Oncol 8:456Google Scholar
  20. 20.
    Mahjoubi M, Sadek H, Francois E et al (1990) Epidermoid anal canal carcinoma: activity of cisplatin and continuous 5-fluorouracil in metastatic and/or locally recurrent disease. Proc Am Soc Clin Oncol 9:441Google Scholar
  21. 21.
    Paliga AA, Chong G, Onerheim R, Spatz A (2010) KRAS and EGFR gene mutation status in anal canal carcinoma. Poster Presentation at Gastrointestinal Cancers Symposium of American Society of Clinical Oncology (ASCO), June 2010Google Scholar
  22. 22.
    Phan LK, Hoff PM (2007) Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum 50:395–398PubMedCrossRefGoogle Scholar
  23. 23.
    Saif MW, Kontny E, Syrigos KN, Shahrokni A (2011) The Role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series. J Oncol Article ID 125467, 5 pagesGoogle Scholar
  24. 24.
    Salem PA, Habboubi N, Anaissie E et al (1985) Effectiveness of cisplatin in the treatment of anal squamous cell carcinoma. Cancer Treat Rep 69:891–893PubMedGoogle Scholar
  25. 25.
    Tanum G (1993) Treatment of relapsing anal carcinoma. Acta Oncol 32:33–35PubMedCrossRefGoogle Scholar
  26. 26.
    Tokar M, Bobilev D, Zalmanov S (2006) Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie 29:30–32PubMedCrossRefGoogle Scholar
  27. 27.
    Van Damme N, Deron P, Van Roy N et al (2010) Epidermal growth factor receptro and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 10 (article 189)Google Scholar
  28. 28.
    Wanebo HJ, Belliveau J, Begossi G, Levy A (2003) Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer. Colorectal Dis 5:508–514PubMedCrossRefGoogle Scholar
  29. 29.
    Wilking N, Petrelli N, Herrera L, Mittelman A (1985) Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol 15:300–302PubMedCrossRefGoogle Scholar
  30. 30.
    You YN, Larson DW, Dozois EJ (2009) Multimodality salvage therapy for anal cancer failing standard chemoradiation. ASCO Meeting 2009Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.TagesTherapieZentrum am Interdisziplinären Tumorzentrum MannheimUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations